TrialCancer medicine2025

An Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor.

Xun Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.